

# **Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017**

<https://marketpublishers.com/r/S87B1B18C84EN.html>

Date: August 2017

Pages: 25

Price: US\$ 3,500.00 (Single User License)

ID: S87B1B18C84EN

## **Abstracts**

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017

### **SUMMARY**

According to the recently published report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017'; Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Estrogen-related receptor alpha (ERR?) or Steroid hormone receptor ERR1 is a nuclear receptor that is encoded by the estrogen related receptor alpha (ESRRA) gene. ERR? regulates genes involved in mitochondrial biogenesis, gluconeogenesis, and fatty acid metabolism. ERR? acts as a transcriptional activator of CYP11B1 and CYP11B2 which indicates that this nuclear receptor may be required for the production of cortisol and aldosterone in the adrenal gland.

The report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017' outlays

comprehensive information on the Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Oncology which include indications Breast Cancer, Obesity, Type 2 Diabetes and Multiple Myeloma (Kahler Disease).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA)

The report reviews Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics and enlists all their major and minor projects

The report assesses Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Overview

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Companies Involved in Therapeutics Development

Lead Pharma Holding BV

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Drug Profiles

CAS-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAS-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Estrogen Related Receptor Alpha for Metabolic Disorders and Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ESRRA for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Dormant Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Lead Pharma Holding BV, H2 2017

Dormant Projects, H2 2017

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

### COMPANIES MENTIONED

Lead Pharma Holding BV



## I would like to order

Product name: Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/S87B1B18C84EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S87B1B18C84EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970